Medical Device Penetration Testing: Scope, Safety, and Evidence

Medical device penetration testing helps a company assess how an attacker could reach device software, connected services, or sensitive information through authorized testing. Consider it before release, after a material change, when a new connection changes exposure, or when a security review calls for current evidence. The right timing depends on the product, its intended use, deployment, and the consequences of disruption. A sound plan examines technical security without losing sight of patient safety.

Talk with Penti about your testing needs

When does a medical device company need penetration testing?

A company should consider a penetration test when it needs evidence about how defined systems withstand realistic, authorized attempts to exploit weaknesses. Common decision points include an initial release, a significant product or architecture change, a new connection, a security incident, a customer assurance request, or a recurring risk review. Testing is especially relevant when a device communicates with a network, mobile application, cloud service, clinical system, or external interface that could affect confidentiality, integrity, or availability.

There is no single schedule or universal trigger that fits every device. Risk depends on intended use, system design, deployment conditions, data, interfaces, and the potential consequences of a failure. A test is one part of a broader security program. It does not replace risk analysis, secure development, vulnerability management, safety engineering, or applicable regulatory and quality processes.

Start with the decision you need to make. Are you asking whether a remote management path is adequately restricted? Whether an account with a limited role can reach another user's information? Whether a new integration changes the exposure of an important function? A defined question helps the team select relevant assets and methods. It also makes the resulting report more useful than a generic request to test everything.

A useful trigger is not always a confirmed vulnerability. A new software release can change authentication, dependencies, interfaces, or data flows even when no one has reported a problem. Conversely, a minor change to a low-risk component may not justify repeating a broad assessment. Ask what changed, what earlier evidence covered, and whether that evidence still represents the system now in use.

What events should prompt a new assessment?

Review changes in exposure and potential impact with product, security, engineering, quality, and safety stakeholders. The following situations are practical prompts to revisit whether existing test evidence remains representative:

• Before an initial release or deployment. Test components and interfaces that will be exposed in the intended environment. Confirm that the authorized test scope reflects the product configuration customers or care teams will actually use.
• After a substantial product change. New features, firmware, authentication flows, operating environments, or communication paths can alter the attack surface. Map the change to earlier findings and decide which components need focused testing and which need broader coverage.
• When a device gains a connection. A cloud feature, mobile application, API, hospital network integration, remote update path, or third-party service can introduce a trust boundary. Treat the connection as a reason to review the path, not as proof that the whole product must automatically be retested.
• After a vulnerability or security incident. Investigate the affected component and adjacent pathways. Testing can help assess remediation and search for related weaknesses, but it does not replace incident response, evidence preservation, or required notifications.
• When deployment conditions change. A device used on a different network or alongside new systems may expose interfaces or dependencies that were not available in the previous environment.
• For a customer, partner, or assurance review. Stakeholders may ask what was assessed, when it was assessed, and what remains unresolved. Match the evidence to the question and explain exclusions clearly.
• As part of an ongoing risk-based program. Periodic assessments can refresh the view as products and dependencies evolve. Set the interval through the organization's risk process and applicable obligations rather than assuming one schedule fits all devices.

Suppose a release adds remote configuration to a monitoring device. The team might first identify the new endpoint, the roles that can use it, the data it accepts, and whether it can alter device behavior. A focused assessment can then examine authentication, authorization, input handling, and the boundary between the management service and the device. The point is to test changed pathways while considering whether those changes also affect other parts of the system.

Teams should also distinguish a vulnerability scan from a penetration test. A scan can identify potential issues across a broad area, while a penetration test examines selected attack paths and validates findings within agreed authorization and scope. The distinction affects what evidence to request and how to allocate remediation. See this guide to vulnerability assessment versus penetration testing for a closer comparison.

Which parts of a medical device should be in scope?

Scope the product as a connected system, not only as a physical unit or a single application. The appropriate boundary depends on the product and written authorization. Begin with an inventory of components, owners, environments, interfaces, data flows, and third parties. Mark each item as included, excluded, or subject to separate approval. This prevents gaps caused by assuming that a device, app, and cloud service are all covered by one phrase in a test request.

Use this table to organize questions, not as a default test scope. Never touch a production device, clinical environment, external provider, or third-party asset unless its owner has given explicit permission and the agreed plan allows it. Third-party cloud boundaries can be difficult to test. MITRE's discussion of cybersecurity risk analysis for medical devices notes the challenge manufacturers face when conducting penetration testing and vulnerability scanning of third-party cloud services. Read the MITRE medical device cybersecurity risk analysis paper in that context.

For each component, consider its role in clinical use and its dependencies. A device may rely on a mobile application for configuration, a cloud platform for data exchange, or a hospital system for identity and workflow. The useful question is not simply whether each component has a vulnerability. Ask how a weakness could be reached, what information or function could be affected, and what controls limit the path.

For broader background on healthcare software, see healthcare application security priorities. If the product handles protected health information, the guide to HIPAA penetration testing offers related context. Requirements depend on the organization's role and circumstances, so do not treat a general article or a test report as legal advice.

How can testing be planned without creating safety risks?

Medical device testing needs explicit safety constraints. The goal is to assess security without creating an unacceptable risk to patients, clinical operations, data, or equipment. Security and product safety owners should agree on the plan before testing begins, especially if the device can affect care or if a test could change configuration, interrupt service, or generate unusual network traffic.

1. Identify device behavior and safety limits. Document what the device does, which functions are safety relevant, and which operating conditions must remain stable. Include known limits on resets, data changes, network load, and update behavior.
2. Choose an appropriate environment. Prefer a representative lab or test environment where feasible. Record how it differs from production, including software versions, network controls, simulated data, and connected services. Do not assume a lab result transfers perfectly to every deployment.
3. Set written authorization and boundaries. Name the assets, methods, accounts, time window, contacts, stop conditions, and prohibited actions. Identify third-party systems and obtain separate permission where needed.
4. Agree on monitoring and escalation. Define who observes device and service behavior, how an unexpected effect is reported, and who can stop the assessment. Make sure the test team knows the escalation route before work starts.
5. Protect information and credentials. Use approved test accounts and data. Agree how logs, evidence, secrets, and sensitive findings will be stored, shared, and removed when no longer needed.
6. Review results with the right owners. Security findings may need product, software, quality, safety, and clinical input. Assess exploitability and possible impact in the product's actual context.

Make the safety controls operational rather than leaving them in a long document no one checks during the test. For example, name a person who can pause work, specify a recognizable stop signal, and set a short process for confirming the device is stable before resuming. If an unexpected reset or data change occurs, stop the relevant activity, preserve the useful evidence, and follow the agreed escalation process. A tabletop discussion can reveal missing contacts or vague stop conditions before technical work begins.

The team should distinguish a test-induced observation from a product failure while preserving enough context to investigate either possibility. Record the time, test activity, device version, environment, and observed behavior. This creates a more reliable basis for deciding what happened and prevents an uncertain observation from being treated as either a confirmed exploit or a harmless test artifact.

For general methods, review types of penetration testing and the practical considerations in API security testing. Those resources explain assessment areas, but the device owner must still define product-specific safety constraints.

What should a useful test report include?

A report should let decision-makers understand what was tested, what was not, how findings were validated, and what action is needed. It should help engineers reproduce and address issues while giving security and product leaders a clear view of risk and remaining uncertainty. Ask for the following details before work begins, so the output is usable by the people who will act on it.

• Scope and exclusions: list tested systems, versions, environments, dates, interfaces, and excluded or third-party components.
• Authorization and constraints: record agreed boundaries, safety controls, test accounts, and significant limits on assessment.
• Findings and supporting evidence: describe affected components, conditions, reproduction steps where appropriate, and evidence behind the conclusion. Handle sensitive details through approved channels.
• Impact and prioritization: explain plausible effects in the product's deployment context. A technical severity score alone may not reflect clinical or operational consequences.
• Recommended remediation: give actionable next steps that map to component ownership, dependencies, and the release process.
• Retest status: distinguish issues fixed and retested from those accepted, deferred, or not yet verified.
• Limitations: state what the test did not establish. A penetration test is a point-in-time assessment of an agreed scope, not proof that a device has no vulnerabilities.

MDIC describes its Medical Device Penetration Testing resource as an industry-developed approach for planning, conducting, and evaluating testing. Teams can consult the MDIC Medical Device Penetration Testing resource when shaping their process. Use it alongside product risk management and applicable requirements, rather than assuming one resource defines every organization's obligations.

Keep evidence connected to remediation. A finding without an owner or decision can linger after the test closes. Track the affected version, responsible team, planned action, decision rationale, and retest outcome. If a finding is not fixed immediately, document the rationale and controls considered, then revisit it through the established risk process. Include enough detail to let the owner know what to do next without distributing sensitive exploit information more widely than necessary.

When a result is reported as fixed, clarify what was retested. A code change may address one input path while leaving a similar path untouched. A retest should identify the updated version and the condition checked, then note whether the original issue was resolved and whether related concerns remain. This gives a reviewer a defensible record rather than a simple status label.

How should teams keep test evidence current?

One assessment cannot keep pace with every product change. Link testing to release review, vulnerability intake, change management, and remediation tracking. When a high-impact component changes, ask whether prior evidence is still representative. When a finding is fixed, verify the change within an agreed scope. When a dependency changes, determine whether the trust boundary or data flow changed as well.

Set a cadence based on product risk and change, then define what causes an earlier review. A team might use a release checklist that asks whether interfaces, authentication, exposed services, third-party components, deployment patterns, or safety constraints changed. A positive answer does not automatically require a full reassessment; it prompts the owner to document the change and decide what level of review is proportionate. Compare continuous versus periodic penetration testing when choosing a practical model. Continuous activity does not mean every component receives a full penetration test at all times. A program can combine monitoring, scanning, targeted tests, and deeper assessments when risk warrants them.

Use the report to improve the process, not only to close individual findings. Repeated problems may point to gaps in design review, secure configuration, testing coverage, or ownership. Share appropriate lessons with engineering and product teams without exposing sensitive details beyond those who need them. A finding pattern can inform which checks should happen earlier in development and which dependencies deserve closer review.

For a wider assurance process, Penti's guide to security assurance verification provides related context. Penti describes its testing as AI-driven with human validation; discuss the proposed scope and deliverables directly to determine whether they fit a particular device and safety environment.

What should a team ask before approving a test?

A short planning review can uncover mismatched expectations before the work begins. Ask the test provider and internal owners to answer these questions in writing:

• Which exact device models, versions, services, accounts, and interfaces are included?
• Which environments and data will be used, and how representative are they of deployment?
• What actions are out of bounds, and who can authorize any change to scope?
• What safety owner will monitor the work, and what conditions require a pause?
• How will third-party permissions and provider-managed boundaries be handled?
• What report format, evidence handling process, and remediation follow-up are expected?
• How will the team distinguish an issue fixed in code from one verified through retesting?

These questions turn a broad request into a decision-ready engagement. If the team cannot name the in-scope versions or the person responsible for stopping work, resolve those gaps before testing. If part of the system cannot be assessed because permission is unavailable, record the boundary and consider other ways to understand that risk, such as reviewing provider evidence or testing the interfaces the organization does control.

Discuss a medical device testing scope

Frequently Asked Questions

Does every medical device need a penetration test before release?

There is no universal answer based only on the product label. Teams should assess intended use, connectivity, software, data, exposure, and applicable obligations, then decide what evidence is appropriate. Consult qualified regulatory, quality, safety, and security advisers for product-specific determinations.

Can a penetration test prove that a device is secure?

No. A test evaluates a defined scope under specific conditions at a point in time. The report should disclose its limits and exclusions. Testing can reveal weaknesses and help validate remediation, but it cannot establish that no unknown issue exists or guarantee future security.

Can testing include a third-party cloud platform?

Only when the scope and authorization allow it. The device company may not own or control every service it depends on. Confirm the provider's rules and permissions, identify what can be tested, and document any component that remains outside the assessment.

How often should a company repeat testing?

Set a risk-based schedule and identify change triggers that call for earlier assessment. Product updates, new interfaces, deployment changes, and significant vulnerabilities can all prompt a review. Any fixed interval should follow applicable requirements and the organization's risk process.

Medical device penetration testing is most useful when its scope reflects real product architecture, safety boundaries, and intended deployment. Plan the assessment with the people who own those risks, then connect each finding to a documented decision and verified follow-up.